• slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Recent News
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day...
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug...